1. Liu LG, Tanaka H, Ito K, Kyo T, Ito T, Kimura A. Chronic myelogenous leukemia with e13a3 (b2a3) type of BCR-ABL transcript having a DNA breakpoint between ABL exons a2 and a3. Am J Hematol. 2003; 74:268–272. PMID:
14635208.
2. Moravcová J, Rulcová J, Polák J, Zemanová Z, Klamová H, Haskovec C. CML patient with rare b 2 a 3 (e 13 a 3) variant of BCR-ABL transcript: complete molecular response to imatinib. Leuk Res. 2005; 29:1365–1366. PMID:
15876454.
3. Pienkowska-Grela B, Woroniecka R, Solarska I, Kos K, Pastwińska A, Konopka L, et al. Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript. Cancer Genet Cytogenet. 2007; 174:111–115. PMID:
17452251.
Article
4. Masuko M, Furukawa T, Abe T, Wada R, Maruyama S, Kitajima T, et al. A chronic myeloid leukemia patient with atypical karyotype and BCR-ABL e13a3 transcript caused by complex chromosome rearrangement. Int J Hematol. 2009; 90:230–234. PMID:
19565180.
Article
5. Achkar WA, Wafa A, Ali BY, Manvelyan M, Liehr T. A rare chronic myeloid leukemia case with Philadelphia chromosome, BCR-ABL e13a3 transcript and complex translocation involving four different chromosomes. Oncol Lett. 2010; 1:797–800. PMID:
22966382.
Article
6. McCarron SL, Langabeer SE, Bolger K, Haslam K, Crampe M, Kelly J, et al. Molecular response to imatinib in chronic myeloid leukaemia with a variant e13a3 BCR-ABL1 fusion. Med Oncol. 2015; 32:452. PMID:
25579165.
Article
7. Franz WM, Berger P, Wang JY. Deletion of an N-terminal regulatory domain of the c-abl tyrosine kinase activates its oncogenic potential. EMBO J. 1989; 8:137–147. PMID:
2496972.
Article
8. Kato JY, Takeya T, Grandori C, Iba H, Levy JB, Hanafusa H. Amino acid substitutions sufficient to convert the nontransforming p60c-src protein to a transforming protein. Mol Cell Biol. 1986; 6:4155–4160. PMID:
2432397.
Article
9. Skorski T, Nieborowska-Skorska M, Wlodarski P, Wasik M, Trotta R, Kanakaraj P, et al. The SH3 domain contributes to BCR/ABL-dependent leukemogenesis in vivo: role in adhesion, invasion, and homing. Blood. 1998; 91:406–418. PMID:
9427693.
Article
10. Gross AW, Zhang X, Ren R. Bcr-Abl with an SH3 deletion retains the ability to induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy. Mol Cell Biol. 1999; 19:6918–6928. PMID:
10490629.
Article